

VASOMEDICAL INC
Form 10-Q
April 14, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended February 28, 2011

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from _____ to _____

Commission File Number: 0-18105

VASOMEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware 11-2871434
(State or other jurisdiction of (IRS Employer Identification
incorporation or organization) Number)

180 Linden Ave., Westbury, New York 11590
(Address of principal executive offices)

Registrant's Telephone Number (516) 997-4600

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.

Large Accelerated Filer Accelerated Filer
Non-Accelerated Filer Smaller Reporting Company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Number of Shares Outstanding of Common Stock, \$.001 Par Value, at April 8, 2011 - 115,016,131

Vasomedical, Inc. and Subsidiaries

INDEX

| | |
|--|----|
| <u>PART I – FINANCIAL INFORMATION</u> | 3 |
| <u>ITEM 1 - FINANCIAL STATEMENTS (unaudited)</u> | 3 |
| <u>CONSOLIDATED CONDENSED BALANCE SHEETS as of February 28, 2011 and May 31, 2010</u> | 3 |
| <u>CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS for the Three and Nine Months Ended February 28, 2011 and February 28, 2010</u> | 4 |
| <u>CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS for the Nine Months Ended February 28, 2011 and February 28, 2010</u> | 5 |
| <u>NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</u> | 6 |
| <u>ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u> | 17 |
| <u>ITEM 4 - CONTROLS AND PROCEDURES</u> | 25 |
| <u>PART II - OTHER INFORMATION</u> | 26 |
| <u>ITEM 6 – EXHIBITS:</u> | 26 |

ITEM 1 - FINANCIAL STATEMENTS

Vasomedical, Inc. and Subsidiaries

CONSOLIDATED CONDENSED BALANCE SHEETS

| ASSETS | February 28, 2011 (unaudited) | May 31, 2010 (audited) |
|---|-------------------------------------|------------------------------|
| CURRENT ASSETS | | |
| Cash and cash equivalents | \$2,073,025 | \$481,679 |
| Short-term investment | 69,709 | 68,850 |
| Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of \$1,437,858 at February 28, 2011, and \$146,961 at May 31, 2010 | 12,688,153 | 473,878 |
| Inventories, net | 1,726,031 | 2,063,769 |
| Financing receivables, net | 18,038 | - |
| Deferred commission expense | 2,283,967 | - |
| Other current assets | 257,047 | 91,848 |
| Total current assets | 19,115,970 | 3,180,024 |
| PROPERTY AND EQUIPMENT , net of accumulated depreciation of \$1,638,910 at February 28, 2011, and \$1,612,098 at May 31, 2010 | 329,972 | 303,038 |
| DEFERRED DISTRIBUTOR COSTS , net of accumulated amortization of \$433,006 at February 28, 2011, and \$338,818 at May 31, 2010 | 155,870 | 250,058 |
| FINANCING RECEIVABLES , net | 31,887 | - |
| OTHER ASSETS | 314,821 | 130,390 |
| | \$19,948,520 | \$3,863,510 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | | |
| CURRENT LIABILITIES | | |
| Accounts payable | \$433,059 | \$271,620 |
| Accrued commissions | 2,694,855 | 29,164 |
| Accrued expenses and other liabilities | 1,010,396 | 239,032 |
| Sales tax payable | 161,396 | 141,884 |
| Deferred revenue - current portion | 11,347,582 | 854,403 |
| Deferred gain on sale-leaseback of building - current portion | 53,245 | 53,245 |
| Accrued professional fees | 77,077 | 86,985 |
| Trade payable due to related party | 241,910 | 240,000 |
| Notes payable | 14,751 | - |
| Total current liabilities | 16,034,271 | 1,916,333 |
| LONG-TERM LIABILITIES | | |
| Notes payable | - | 1,250,000 |
| Deferred revenue | 1,261,586 | 172,945 |
| Accrued rent expense | 14,887 | 17,655 |
| Deferred gain on sale-leaseback of building | 22,185 | 62,121 |
| Other long-term liabilities | 261,114 | 11,900 |
| Total long-term liabilities | 1,559,772 | 1,514,621 |
| COMMITMENTS AND CONTINGENCIES (NOTE N) | | |

STOCKHOLDERS' EQUITY

| | | |
|---|--------------|--------------|
| Preferred stock, \$.01 par value; 1,000,000 shares authorized; 314,649 issued and outstanding at February 28, 2011 | 3,146 | - |
| Common stock, \$.001 par value; 250,000,000 shares authorized; 111,816,131 shares at February 28, 2011 and 110,271,113 at May 31, 2010 issued and outstanding | 111,816 | 110,271 |
| Additional paid-in capital | 54,511,712 | 48,958,737 |
| Accumulated deficit | (52,272,197) | (48,636,452) |
| Total stockholders' equity | 2,354,477 | 432,556 |
| | \$19,948,520 | \$3,863,510 |

The accompanying notes are an integral part of these consolidated condensed financial statements.

Page 3

Vasomedical, Inc. and Subsidiaries

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)

| | Nine months ended February 28, | | Three months ended February 28, | |
|---|--------------------------------|---------------------|---------------------------------|---------------------|
| | 2011 | 2010 | 2011 | 2010 |
| Revenues | | | | |
| Equipment sales | \$2,484,488 | \$1,700,440 | \$571,213 | \$589,283 |
| Equipment rentals and services | 1,702,709 | 1,562,459 | 558,019 | 518,115 |
| Commissions | 6,740,399 | - | 4,721,775 | - |
| Total revenues | 10,927,596 | 3,262,899 | 5,851,007 | 1,107,398 |
| Cost of revenues | | | | |
| Cost of sales, equipment | 1,595,115 | 835,224 | 403,931 | 295,773 |
| Cost of equipment rentals and services | 710,845 | 617,451 | 249,136 | 177,901 |
| Cost of commissions | 1,508,418 | - | 1,084,505 | - |
| Total cost of revenues | 3,814,378 | 1,452,675 | 1,737,572 | 473,674 |
| Gross profit | 7,113,218 | 1,810,224 | 4,113,435 | 633,724 |
| Operating expenses | | | | |
| Selling, general and administrative | 10,184,835 | 1,966,155 | 3,671,288 | 667,123 |
| Research and development | 328,267 | 306,086 | 111,799 | 101,693 |
| Total operating expenses | 10,513,102 | 2,272,241 | 3,783,087 | 768,816 |
| Operating income/(loss) | (3,399,884) | (462,017) | 330,348 | (135,092) |
| Other income/(expenses) | | | | |
| Interest and financing costs | (7,852) | - | (1,356) | - |
| Interest and other income, net | 17,400 | 86,155 | 1,256 | (297) |
| Amortization of deferred gain on sale-leaseback of building | - | 39,934 | 13,311 | 13,311 |
| Total other income, net | 49,482 | 126,089 | 13,211 | 13,014 |
| Income/(loss) before income taxes | (3,350,402) | (335,928) | 343,559 | (122,078) |
| Income tax benefit/(expense), net | (10,356) | 34,313 | (3,026) | 18,507 |
| Net income/(loss) | (3,360,758) | (301,615) | 340,533 | (103,571) |
| Preferred stock dividends | (274,987) | - | (122,876) | - |
| Net income/(loss) applicable to common stockholders | \$(3,635,745) | \$(301,615) | \$217,657 | \$(103,571) |
| Earnings/(loss) per common share | | | | |
| - basic | \$(0.03) | \$(0.00) | \$0.00 | \$(0.00) |
| - diluted | \$(0.03) | \$(0.00) | \$0.00 | \$(0.00) |
| Weighted average common shares outstanding | | | | |
| - basic | 110,906,754 | 99,843,004 | 111,168,353 | 99,843,004 |

Edgar Filing: VASOMEDICAL INC - Form 10-Q

| | | | | |
|-----------|-------------|------------|-------------|------------|
| - diluted | 110,906,754 | 99,843,004 | 116,085,279 | 99,843,004 |
|-----------|-------------|------------|-------------|------------|

The accompanying notes are an integral part of these consolidated condensed financial statements.

Page 4

Vasomedical, Inc. and Subsidiaries

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)

| | Nine months ended February 28, | |
|--|-----------------------------------|--------------|
| | 2011 | 2010 |
| Cash flows used in operating activities | | |
| Net loss | \$(3,360,758) | \$(301,615) |
| Adjustments to reconcile net loss to net cash used in operating activities | | |
| Depreciation and amortization of property and equipment | 108,184 | 85,166 |
| Amortization of deferred gain on sale-leaseback of building | (39,934) | (39,934) |
| Provision for/(recovery of) doubtful accounts and commission adjustments | 1,290,897 | (37,208) |
| Amortization of deferred distributor costs | 94,188 | 94,189 |
| Share-based compensation | 305,035 | 27,404 |
| Changes in operating assets and liabilities: | | |
| Accounts and other receivables | (13,505,172) | (91,184) |
| Inventories, net | 368,215 | (420,678) |
| Financing receivables, net | (49,925) | - |
| Deferred commission expense | (2,283,967) | - |
| Other current assets | (64,823) | 59,289 |
| Other assets | (217,759) | - |
| Accounts payable | 161,439 | 226,789 |
| Accrued commissions | 2,665,691 | 32,785 |
| Accrued expenses and other liabilities | 629,008 | (89,762) |
| Sales tax payable | 19,512 | (6,999) |
| Deferred revenue | 11,581,820 | (209,895) |
| Accrued professional fees | (9,908) | 16,870 |
| Trade payable due to related party | 1,910 | (20,000) |
| Accrued rent expense | (2,768) | 1,557 |
| Other long-term liabilities | 249,214 | - |
| Net cash used in operating activities | (2,059,901) | (673,226) |
| Cash flows provided by (used in) investing activities | | |
| Purchases of property and equipment | (132,270) | (21,729) |
| Purchases of short-term investments | (859) | (68,850) |
| Redemption of short-term investments | - | 370,523 |
| Net cash provided by (used in) investing activities | (133,129) | 279,944 |
| Cash flows provided by financing activities | | |
| Issuance of note payable | 250,000 | - |
| Repayment of note payable | (250,000) | - |
| Proceeds from preferred stock issuance | 3,784,376 | - |
| Net cash provided by financing activities | 3,784,376 | - |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 1,591,346 | (393,282) |
| Cash and cash equivalents - beginning of period | 481,679 | 544,057 |
| Cash and cash equivalents - end of period | \$2,073,025 | \$150,775 |

SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION

| | | |
|-------------------|---------|---------|
| Interest paid | 7,852 | \$- |
| Income taxes paid | \$7,526 | \$4,111 |

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES

| | | |
|--|--------------|-----------|
| Inventories transferred to/(from) property and equipment, attributable to operating leases, net | \$30,477 | \$72,132 |
| Issuance of note for purchase of insurance policy | \$14,751 | \$- |
| Conversion of notes payable to preferred stock | \$1,250,000 | \$- |
| Accrued preferred stock dividends | \$(274,987) | \$- |
| Issuance of preferred stock in satisfaction of accrued dividend | \$100,768 | \$- |
| Trade payable due to related party payable in common stock | \$- | \$469,450 |

The accompanying notes are an integral part of these consolidated condensed financial statements.

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

NOTE A - ORGANIZATION AND PLAN OF OPERATIONS

Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. In 1995, we have been primarily engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems based on our unique proprietary technology currently indicated for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure (“CHF”), acute myocardial infarction (i.e., heart attack, (MI)) and cardiogenic shock. In April 2010, the Company, through a wholly-owned subsidiary Vaso Diagnostics d/b/a Vaso Healthcare, organized a group of medical device sales professionals in the hope of entering into the sales and representation business for other equipment manufacturers. On May 19, 2010, Vaso Healthcare signed a sales representative agreement with GE Healthcare (the “GEHC Agreement”), the healthcare business unit of General Electric Company (NYSE: GE), for the sale of select GE Healthcare Diagnostic Imaging products. Under the GEHC Agreement, Vaso Healthcare has been appointed the exclusive representative for these products to specific market segments in the 48 contiguous states of the United States and the District of Columbia. The GEHC Agreement has an initial term of three years commencing July 1, 2010, subject to extension and also subject to earlier termination under certain circumstances. We now report Vaso Healthcare activities under our Sales Representation reportable segment and EECP® and other medical device operations under our Equipment reportable segment (See Note D).

NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES

Basis of Presentation and Use of Estimates

The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the consolidated condensed financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these consolidated condensed financial statements should be read in connection with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report for the year ended May 31, 2010, as filed with the SEC on Form 10-K/A. These consolidated condensed financial statements include the accounts of the Companies over which we exercise control. In the opinion of management, the accompanying consolidated condensed financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated condensed financial statements, the disclosure of contingent assets and liabilities in the consolidated condensed financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.

Significant Accounting Policies

Note B of the Notes to Consolidated Financial Statements, included in the Annual Report on Form 10-K/A for the year ended May 31, 2010, includes a summary of the significant accounting policies used in the preparation of the consolidated financial statements. The following policies are effective as of June 1, 2010 and have been implemented by the Company for the nine and three months ended February 28, 2011.

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

Newly-Adopted Accounting Policy

Effective June 1, 2010, the Company adopted Accounting Standards Update No. 2009-13, "Revenue Recognition (Topic 605)", which revised the authoritative guidance for revenue arrangements with multiple deliverables. This revised authoritative guidance requires companies to allocate revenue in arrangements involving multiple deliverables based on the estimated selling price of each deliverable, even though such deliverables are not sold separately either by a company itself or other vendors. This revised authoritative guidance eliminates the requirement that all undelivered elements must have objective and reliable evidence of fair value before a company can recognize the portion of the overall arrangement fee that is attributable to items that already have been delivered. As a result, the new guidance may allow some companies to recognize revenue on transactions that involve multiple deliverables earlier than under previous requirements. This revised authoritative guidance was effective for revenue arrangements entered into or materially modified in fiscal years beginning on or after December 15, 2009. The adoption of this guidance did not have an impact on the Company's consolidated condensed financial statements.

Effective December 1, 2010, the Company adopted Accounting Standards Update ("ASU") No. 2010-20, "Receivables (Topic 310): Disclosures about the Credit Quality of Financing Receivables and the Allowance for Credit Losses," (ASU 2010-20). ASU 2010-20 requires enhanced disclosures about an entity's credit quality of financing receivables and the related allowance for credit losses. The provisions of ASU 2010-20 require expansion of the Company's disclosures on the credit quality of its financing receivables and the allowance for credit losses. The Company does not expect the adoption of ASU 2010-20 to have a material effect on its consolidated condensed financial statements.

Revenue and Expense Recognition for Vaso Healthcare

The Company recognizes commission revenue associated with our Sales Representation segment (see Note D) when persuasive evidence of an arrangement exists, service has been rendered, the price is fixed or determinable and collectability is reasonably assured. These conditions are deemed to be met when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable under the agreement with GE Healthcare ("GEHC") in advance of the customer acceptance of the equipment are recorded as accounts receivable and deferred revenue in the consolidated condensed balance sheet. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded. Commission expense is recognized when the corresponding commission revenue is recognized.

Reclassifications

Certain reclassifications have been made to prior period amounts to conform with the current period presentation.

NOTE C - LIQUIDITY

During the last several years, the Company has incurred operating losses. We have sought to achieve profitability by expanding our business opportunities through the introduction of additional products and the development of the Vaso Healthcare business.

In the last couple of years, the Company has been looking to diversify its business, including offering additional medical devices in its product portfolio, and has since introduced patient monitoring devices (the BIOX series Holter,

ABP recorders and analysis software) and patient management devices (the EZ ECG and EZ O2 products) into the U.S. market.

Page 7

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

In the first three quarters of fiscal 2011, the Company issued Series E convertible preferred stock (see Note M) to finance the operation of its Sales Representation segment. In addition, under the terms of our agreement with GEHC, we are entitled to commissions on certain undelivered sales orders received by GEHC prior to our agreement and transferred to us from GEHC as of September 30, 2010. These transferred orders, though subject to various risks including potential cancellation and changes in credit worthiness and availability, as well as the Company's continued compliance under the GEHC Agreement, generated commission revenue of \$2.0 million from October 2010 to February 2011, and are expected to generate additional commission revenues estimated to range from \$2.1 million to \$3.0 million over approximately one or more years.

Based on our current operations through February 28, 2011, we believe internally generated funds from our Equipment and Sales Representation segments will be sufficient for the Company to continue operations through at least February 28, 2012. At March 31, 2011, the Company had cash and cash equivalents in excess of \$9.75 million.

NOTE D – SEGMENT REPORTING

The Company views its business in two segments – the Equipment segment and the Sales Representation segment. The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices. The Sales Representation segment operates through the Vaso Healthcare subsidiary and is engaged solely in the execution of the Company's responsibilities under our agreement with GEHC. The Company evaluates segment performance based on operating income. Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment. There are no intersegment revenues. Summary financial information for the segments is set forth below:

| | As of or for the three months ended February 28, 2011 (unaudited) | | | |
|-------------------------------------|--|---------------------------|--------------|---------------|
| | Sales | | | Consolidated |
| | Equipment Segment | Representation Segment | Corporate | |
| Revenues from external customers | \$ 1,129,232 | \$ 4,721,775 | \$ - | \$ 5,851,007 |
| Operating income/(loss) | \$(176,579) | \$ 669,164 | \$(162,237) | \$ 330,348 |
| Total assets | \$5,369,045 | \$ 14,482,600 | \$96,875 | \$ 19,948,520 |
| Accounts and other receivables, net | \$738,690 | \$ 11,949,463 | \$ - | \$ 12,688,153 |
| Deferred commission expense | \$ - | \$ 2,283,967 | \$ - | \$ 2,283,967 |

| | As of or for the three months ended February 28, 2010 (unaudited) | | | |
|----------------------------------|--|---------------------------|--------------|--------------|
| | Sales | | | Consolidated |
| | Equipment Segment | Representation Segment | Corporate | |
| Revenues from external customers | \$ 1,107,398 | \$ - | \$ - | \$ 1,107,398 |
| Operating loss | \$(1,074) | \$ - | \$(134,018) | \$(135,092) |
| Total assets | \$4,059,149 | \$ - | \$ 11,250 | \$ 4,070,399 |

Edgar Filing: VASOMEDICAL INC - Form 10-Q

| | | | | |
|-------------------------------------|-----------|------|------|------------|
| Accounts and other receivables, net | \$787,943 | \$ - | \$ - | \$ 787,943 |
| Deferred commission expense | \$- | \$ - | \$ - | \$ - |

Page 8

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

As of or for the nine months ended February 28, 2011
(unaudited)

| | Equipment Segment | Sales Representation Segment | Corporate | Consolidated |
|-------------------------------------|----------------------|------------------------------------|--------------|----------------|
| Revenues from external customers | \$4,187,197 | \$ 6,740,399 | \$- | \$ 10,927,596 |
| Operating loss | \$(162,365) | \$(2,963,588) | \$(273,931) | \$(3,399,884) |
| Total assets | \$5,369,045 | \$ 14,482,600 | \$96,875 | \$ 19,948,520 |
| Accounts and other receivables, net | \$738,690 | \$ 11,949,463 | \$- | \$ 12,688,153 |
| Deferred commission expense | \$- | \$ 2,283,967 | \$- | \$ 2,283,967 |

As of or for the nine months ended February 28, 2010
(unaudited)

| | Equipment Segment | Sales Representation Segment | Corporate | Consolidated |
|-------------------------------------|----------------------|------------------------------------|--------------|--------------|
| Revenues from external customers | \$3,262,899 | \$ - | \$- | \$ 3,262,899 |
| Operating loss | \$(127,904) | \$ - | \$(334,113) | \$(462,017) |
| Total assets | \$4,059,149 | \$ - | \$11,250 | \$ 4,070,399 |
| Accounts and other receivables, net | \$787,943 | \$ - | \$- | \$ 787,943 |
| Deferred commission expense | \$- | \$ - | \$- | \$ - |

NOTE E – SHARE-BASED COMPENSATION

The Company complies with ASC Topic 718 “Compensation – Stock Compensation” (“ASC 718”), which requires all share-based awards to employees, including grants of employee stock options, to be recognized in the consolidated condensed financial statements based on their estimated fair values.

During the three-month period ended February 28, 2011, the Company’s Board of Directors granted 250,000 restricted shares of common stock, valued at \$77,500 with a vesting period of one year, to a consultant, and 200,000 shares of common stock valued at \$62,000 to outside directors. No shares of common stock were issued to outside directors, employees, or outside consultants during the three-month period ended February 28, 2010.

During the nine-month period ended February 28, 2011, the Company’s Board of Directors granted, under the 2010 Stock Plan (see Note M), 4,400,000 restricted shares of common stock valued at \$849,000 to employees and consultants. Shares valued at \$65,550 vested immediately and the remainder vest over three years. During the nine-month period ended February 28, 2011, 1,000,000 shares of common stock valued at \$255,000 were granted to outside directors and consultants, of which 250,000 shares valued at \$77,500 will vest over one year. No shares of common stock were issued to outside directors, employees, or outside consultants during the nine-month period ended February 28, 2010.

During the nine-month period ended February 28, 2011, the Company’s Board of Directors did not grant any non-qualified stock options. During the three and nine-month periods ended February 28, 2010, the Company’s Board

of Directors granted non-qualified stock options of 200,000 shares to one outside director and 250,000 shares to one officer. These options vested immediately upon grant and have a period of five years.

Share-based compensation expense recognized under ASC 718 was \$96,420 and \$305,035 for the three and nine months ended February 28, 2011, respectively. These expenses are included in cost of revenues; selling, general, and administrative expenses; and research and development expenses in the consolidated condensed statements of operations. Share-based compensation expense was \$27,404 for the three and nine month periods ended February 28, 2010.

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

NOTE F – EARNINGS/(LOSS) PER COMMON SHARE

Basic loss per common share is computed as loss applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period. Diluted loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.

Basic and diluted loss per common share were \$0.03 and less than \$0.01 for the nine months ended February 28, 2011 and 2010, respectively, and earnings of less than \$0.01 and a loss of less than \$0.01 for the three months ended February 28, 2011 and 2010, respectively.

Diluted earnings per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common shares. A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:

| | Nine months ended February 28, | | Three months ended February 28, | |
|--|-----------------------------------|------------|------------------------------------|------------|
| | 2011 | 2010 | 2011 | 2010 |
| Basic weighted average shares outstanding | 110,906,754 | 99,843,004 | 111,168,353 | 99,843,004 |
| Dilutive effect of share-based compensation and warrants | - | - | 4,916,926 | - |
| Dilutive weighted average shares outstanding | 110,906,754 | 99,843,004 | 116,085,279 | 99,843,004 |

Stock options, warrants, convertible preferred stock, and common stock grants, in accordance with the following table, were excluded from the computation of diluted loss per share for the nine and three months ended February 28, 2011 and February 28, 2010.

| | Nine months ended February 28, | | Three months ended February 28, | |
|-----------------------------|-----------------------------------|-----------|------------------------------------|-----------|
| | 2011 | 2010 | 2011 | 2010 |
| Stock options | 1,888,776 | 3,048,239 | 338,776 | 3,048,239 |
| Warrants | 4,285,714 | 6,540,252 | - | 6,540,252 |
| Convertible preferred stock | 31,726,449 | - | 31,726,449 | - |
| Common stock grants | 4,110,000 | - | - | - |
| | 42,010,939 | 9,588,491 | 32,065,225 | 9,588,491 |

NOTE G – FAIR VALUE MEASUREMENTS

The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

The following tables present information about the Company's assets and liabilities measured at fair value as of February 28, 2011 and May 31, 2010:

| | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Balance as of February 28, 2011 |
|--|---|---|--|---|
| Assets | | | | |
| Cash equivalents invested in money market fund (included in cash and cash equivalents) | \$21,241 | \$- | \$ - | \$21,241 |
| Investment in certificates of deposit (included in short-term investment) | 69,709 | - | - | 69,709 |
| | \$90,950 | \$- | \$ - | \$90,950 |

| | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Balance as of May 31, 2010 |
|--|---|---|--|-------------------------------------|
| Assets | | | | |
| Cash equivalents invested in money market fund (included in cash and cash equivalents) | \$21,516 | \$- | \$ - | \$21,516 |
| Investment in certificates of deposit (included in short-term investment) | 68,850 | - | - | 68,850 |
| | \$90,366 | \$- | \$ - | \$90,366 |

The fair values of the Company's cash equivalents invested in money market fund are determined through market, observable and corroborated sources.

NOTE H – ACCOUNTS AND OTHER RECEIVABLES

The following table presents information regarding the Company's accounts and other receivables as of February 28, 2011 and May 31, 2010:

| | February 28, 2011 (unaudited) | May 31, 2010 (audited) |
|--------------------|-------------------------------------|------------------------------|
| Trade receivables | \$14,121,311 | \$587,898 |
| Due from employees | 4,700 | 32,941 |

| | | |
|--|--------------|------------|
| Allowance for doubtful accounts and commission adjustments | (1,437,858) | (146,961) |
| | \$12,688,153 | \$473,878 |

Trade receivables include amounts due for shipped products and services rendered. Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.

Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC agreement. Due from employees primarily reflects commission advances made to sales personnel.

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

NOTE I – INVENTORIES

Inventories, net of reserves, consist of the following:

| | February 28, 2011 (unaudited) | May 31, 2010 (audited) |
|-----------------|-------------------------------------|------------------------------|
| Raw materials | \$514,142 | \$585,991 |
| Work in process | 603,857 | 608,658 |
| Finished goods | 608,032 | 869,120 |
| | \$1,726,031 | \$2,063,769 |

At February 28, 2011 and May 31, 2010, the Company had reserves for excess and obsolete inventory of \$421,432 and \$358,972, respectively.

NOTE J – FINANCING RECEIVABLES, NET

At February 28, 2011, the Company had financing receivables of \$49,925, net of unearned interest of \$5,875. These financing receivables were generated by a sales-type lease of our EECPC® equipment in our Equipment Segment for a term of three years ending September 1, 2013. At February 28, 2011 there were no past due amounts on these financing receivables and the Company has consequently made no provision for credit loss. At May 31, 2010 the Company had no financing receivables.

NOTE K - DEFERRED REVENUE

The changes in the Company's deferred revenues are as follows:

| | Nine months ended February 28, | | Three months ended February 28, | |
|---|-----------------------------------|-------------|------------------------------------|-------------|
| | 2011 | 2010 | 2011 | 2010 |
| Deferred revenue at the beginning of the period | \$1,027,348 | \$1,287,707 | \$6,597,393 | \$1,123,487 |
| Additions: | | | | |
| Deferred extended service contracts | 989,629 | 798,470 | 427,813 | 274,449 |
| Deferred in-service and training | 22,500 | 17,500 | 7,500 | 5,000 |
| Deferred service arrangements | 68,000 | 62,500 | 18,000 | 10,000 |
| Deferred commission revenues | 16,350,595 | - | 9,174,943 | - |
| Recognized as revenue: | | | | |
| Deferred extended service contracts | (942,045) | (968,926) | (310,774) | (302,489) |
| Deferred in-service and training | (17,500) | (25,000) | (7,500) | (5,000) |
| Deferred service arrangements | (42,983) | (94,439) | (15,667) | (27,635) |
| Deferred commission revenues | (4,846,376) | - | (3,282,540) | - |
| Deferred revenue at end of period | 12,609,168 | 1,077,812 | 12,609,168 | 1,077,812 |
| Less: current portion | 11,347,582 | 873,661 | 11,347,582 | 873,661 |
| Long-term deferred revenue at end of period | \$1,261,586 | \$204,151 | \$1,261,586 | \$204,151 |

NOTE L – RELATED-PARTY TRANSACTIONS

On June 21, 2007, we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. (“Kerns”). Concurrently with our entry into the Securities Purchase Agreement, we also entered into a Distribution Agreement and a Supplier Agreement with Living Data Technology Corporation (“Living Data”), an affiliate of Kerns.

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

We sold to Kerns, pursuant to the Securities Purchase Agreement, 21,428,572 shares of our common stock at \$.07 per share for a total purchase price of \$1,500,000, as well as a five-year warrant to purchase 4,285,714 shares of our common stock at an initial exercise price of \$.08 per share (“the Warrant”). The agreement further provided for the appointment to our Board of Directors of two representatives from Kerns. In furtherance thereof, Dr. Jun Ma and Mr. Simon Srybnik, Chairman of both Kerns and Living Data, were appointed members of our Board of Directors. On July 10, 2007, the Board of Directors appointed Mr. Behnam Movaseghi, Treasurer and Chief Financial Officer of Kerns, to our Board of Directors. Mr. Movaseghi and Mr. Srybnik were each directly involved in the transactions between Living Data, Kerns and the Company, with respect to the Securities Purchase Agreement, the Distribution Agreement and the Supplier Agreement, as well as consulting services to the Company with no compensation. On October 15, 2008, Dr. Jun Ma was appointed Chief Executive Officer.

Pursuant to the Distribution Agreement, as amended, we have become the exclusive worldwide distributor of the AngioNew EECP® systems manufactured by Living Data. As additional consideration for such agreement, we agreed to issue a total of 9,990,840 shares of our common stock to Living Data. The Distribution Agreement has an initial term extending through May 31, 2012.

Pursuant to the Supplier Agreement, Living Data became our exclusive supplier of the external counterpulsation therapy systems that we market under the registered trademark EECP®. On February 28, 2010, the Supplier Agreement was terminated and, in connection with the termination, the Company purchased Living Data’s remaining inventory at cost (\$469,450), which was paid in 7,824,167 shares of common stock valued at the closing price on the termination date. Prior to termination, the Company purchased in fiscal 2010 additional EECP® therapy systems for \$40,000 from Living Data. Payment terms on certain purchases prior to 2010, plus \$1,910 in commissions for sales of certain BIOX products, leave a balance of \$241,910 and \$240,000 in Trade Payable to Related Party on the accompanying consolidated condensed balance sheets as of February 28, 2011 and May 31, 2010, respectively.

Pursuant to a Registration Rights Agreement, we granted to Kerns and Living Data, subject to certain restrictions, “piggyback registration rights” covering the shares sold to Kerns as well as the shares issuable upon exercise of the Warrant and the shares issued to Living Data.

On February 28, 2011, David Lieberman was appointed by the Board of Directors as a director of the Company to serve as the Vice Chairman of the Board. Mr. Lieberman has been a practicing attorney in the State of New York for in excess of 35 years specializing in corporation and securities law. He is currently a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which firm performs legal services for the Company.

During the three and nine months ended February 28, 2011 the Company sold, or issued as dividends, 5,269 and 246,870 shares, respectively, of Series E Preferred Stock (see Note M) to directors, management, and other related parties of the Company.

NOTE M – STOCKHOLDERS’ EQUITY

Common Stock

On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the “2010 Plan”) for officers, directors, employees and consultants of the Company. The stock issuable under the 2010 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock. The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares.

The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as a bonus for services rendered to the Company.

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares. Options granted under the 2010 Plan may be either incentive stock options or non-qualified stock options. The option price shall be 100% of the fair market value of the common stock on the date of the grant (or in the case of incentive stock options granted to any individual stockholder possessing more than 10% of the total combined voting power of all voting stock of the Company, 110% of such fair market value). The term of any option may be fixed by the Board of Directors, or its authorized committee, but in no event shall it exceed five years from the date of grant. Options are exercisable upon payment in full of the exercise price, either in cash or in common stock valued at fair market value on the date of exercise of the option.

In July 2010, 3,750,000 restricted shares of common stock were granted under the 2010 Plan to non-officer employees and consultants of the Company. As of February 28, 2011, 195,000 shares have been forfeited. In September 2010, 650,000 restricted shares of common stock were granted under the 2010 Plan to officers of the Company. No options were issued under the 2010 Plan during the three or nine months ended February 28, 2010.

Preferred Stock

On June 24, 2010, the Company filed a Certificate of Designations of Preferences and Rights of Series E Convertible Preferred Stock (“Certificate of Designations”), as authorized by the Board of Directors, designating 350,000 shares of its 1,000,000 shares of preferred stock as Series E Convertible Preferred Stock (“Series E Preferred”). The following is a summary of the powers, designations, preferences and other rights of the Series E Preferred.

- i. Face Amount. The face amount per share of the Series E Preferred is \$16.00.
- ii. Dividends. Cumulative dividends will accrue at a rate of 5% per annum, payable semi-annually in additional shares of the Series E Preferred. Dividends on the Series E Preferred will be paid in preference to any dividends paid to the holders of the Company’s Common Stock or any other series of the Company’s preferred stock made junior to the Series E Preferred.
- iii. Liquidation Preference. On any liquidation, dissolution or winding-up of the Corporation, the holders of the Series E Preferred will receive payment of twice the aggregate face amount thereof, plus all accrued and unpaid dividends, before any payments or distributions are paid or provided for the Company’s Common Stock or any other series of the Company’s preferred stock made junior to the Series E Preferred. In the event of a sale of all or substantially all the Company’s stock or assets, the holders of the Series E Preferred will receive payment of 1.2 times the aggregate face amount thereof, plus all accrued and unpaid dividends, before any payments or distributions are paid or provided for the Company’s Common Stock or any other series of the Company’s preferred stock made junior to the Series E Preferred.
- iv. Conversion Rights. Each share of the Series E Preferred will be convertible at any time or from time to time at the holder’s option commencing six months from the issuance date into 100 shares of Common Stock (an exercise price of \$.16 per share of Common Stock, the “Conversion Price”), subject to anti-dilution adjustment as set forth below. Commencing at any time one year from the issuance date, one-half 50% of the Series E Preferred will be automatically converted into 100 shares of Common Stock for each share of Series E Preferred if the closing market price of the Common Stock is 3 times the Conversion Price for 30 consecutive trading days and the average daily trading volume during those 30 days is 250,000 shares or greater. Notwithstanding the foregoing, the Series E Preferred shall be automatically converted into Common Stock on June 1, 2015.
- v. Voting Rights. Investors in the Series E Preferred will have voting rights in the ratio of 100 votes for each share of Series E Preferred and shall vote together with the Common Stock as a single class.
- vi.

Anti-Dilution Adjustments. The 100-to-1 conversion ratio of the Series E Preferred will be subject to proportional adjustment for stock dividends, stock splits and other similar changes in capitalization. If the Company issues or sells shares of its capital stock for consideration of a price of less than the lesser of its then current market price or the applicable Conversion Price, the Conversion Price shall be adjusted to be such lower price at which the Company issued or sold shares of its capital stock; provided, however, that the Company shall have the right to issue shares and options under its option plans.

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

During the nine months ended February 28, 2011, the Company issued an aggregate of 314,649 shares of its Series E Preferred. 78,125 of the shares were issued to cover the cancellation of the Notes Payable outstanding at May 31, 2010. Dividends totaling \$142,356 have been accrued for the nine months ended February 28, 2010 of which \$100,768 were paid on January 1, 2011 through the issuance of 6,298 shares of the Company's Series E Preferred pursuant to the Certificate of Designations. Additional dividends totaling \$61,922 and \$132,631 were recorded in recognition of the embedded beneficial conversion feature associated with the Series E Preferred during the three and nine months ended February 28, 2011, respectively.

NOTE N – COMMITMENTS AND CONTINGENCIES

Sales representation agreement

The GEHC Agreement is for an initial term of three years commencing July 1, 2010, subject to extension and also subject to earlier termination under certain circumstances. These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements. Under the terms of the agreement the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.

Leases

On August 15, 2007, we sold our facility in Westbury, New York under a five-year leaseback agreement. Vaso Healthcare also leases facilities in Greensboro, North Carolina pursuant to a lease which expires in May 2013. Future rental payments under these operating leases aggregate approximately as follows:

For the years ended:

| | |
|--------------|-----------|
| May 31, 2011 | \$50,946 |
| May 31, 2012 | 209,353 |
| May 31, 2013 | 88,323 |
| Total | \$348,622 |

NOTE O - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS NOT YET EFFECTIVE

As of February 28, 2011, the Company believes that there are no recently issued accounting pronouncements not yet effective that will have an impact on the Company's consolidated condensed financial statements.

NOTE P – SUBSEQUENT EVENTS

Consulting agreement

On February 28, 2011, the Company's Board of Directors approved a Consulting Agreement between Vasomedical, Inc. and Edgary Consultants, LLC ("Consultant") for a term commencing on March 1, 2011 and terminating on February 28, 2013 (the "Agreement"). The Agreement provides for the engagement of Consultant to assist the Company in seeking broader reimbursement coverage of EECPC® therapy. More specifically, Consultant will be

assisting the Company in the following areas:

Page 15

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

1. Engaging the adoption of EECP® therapy as a first line option for FDA cleared indications as it relates to CCS Class III/IV angina with a major commercial healthcare third-party payer.
2. Engaging a major commercial healthcare payer to formally collaborate and co-sponsor a study with Vasomedical for the efficacy, efficiency and/or cost effectiveness of the EECP® therapy for NYHA Class II/III heart failure.
3. Engaging final approval from the Centers for Medicare and Medicaid Services (“CMS”) of EECP® therapy as a first line treatment for CCS Class III/IV angina.
4. Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for CCS Class II angina; and
5. Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for NYHA Class II/III heart failure.

In consideration for the services to be provided by Consultant under the Agreement, the Company has agreed to issue to Consultant or its designees, approximately 10% of the outstanding capital stock of the Company, of which the substantial portion (in excess of 82%) is performance based as referenced above. In conjunction with the agreement, Mr. Rios was appointed a director of the Company, and 3,000,000 shares of restricted common stock were issued in March 2011.

Employment agreement

On March 21, 2011, the Company entered into an Employment Agreement with its President and Chief Executive Officer, for a three-year term ending on March 14, 2014 (the “Employment Agreement”). The Employment Agreement provides for annual compensation of \$200,000, eligibility for annual bonuses and long-term incentive awards, and certain severance benefits in the event of termination prior to the expiration date of the Employment Agreement.

Stock Issuance

In March 2011, the Company granted 116,279 shares of fully vested common stock valued at \$50,000 to an outside director.

Vasomedical, Inc. and Subsidiaries

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC Agreement and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

General Overview

Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. Since 1995, we have been primarily engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems based on our unique proprietary technology currently indicated for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure (“CHF”), acute myocardial infarction (i.e., heart attack, (“MI”)) and cardiogenic shock.

During the last several years, the Company has incurred operating losses. We have sought to achieve profitability by expanding our business opportunities through the introduction of additional products and the development of the Vaso Healthcare business.

In the last couple of years, the Company has been looking to diversify its business, including offering additional medical devices in its product portfolio, and has since introduced patient monitoring devices (the BIOX series Holter, ABP recorders and analysis software) and patient management devices (the EZ ECG and EZ O2 products) into the U.S. market.

In April 2010, the Company, through a wholly-owned subsidiary Vaso Diagnostics d/b/a Vaso Healthcare, organized a group of medical device sales professionals in the hope of entering into the sales and representation business for other equipment manufacturers. On May 19, 2010, Vaso Healthcare signed a sales representative agreement with GE Healthcare (the “GEHC Agreement”), the healthcare business unit of the General Electric Company (NYSE: GE), for the sale of select GE Healthcare Diagnostic Imaging products. Under the GEHC Agreement, Vaso Healthcare has been appointed the exclusive representative for these products to specific market segments in the 48 contiguous states of the United States and the District of Columbia. The GEHC Agreement is for an initial term of three years commencing July 1, 2010, subject to extension and also subject to earlier termination under certain circumstances. These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements. We now report Vaso Healthcare activities under our Sales Representation reportable segment and EECP® and other medical device operations under our Equipment reportable segment (See Note D).

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon the accompanying unaudited consolidated condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Although these estimates are based on our knowledge of current events, our actual amounts and results could differ from those estimates. The estimates made are based on historical factors, current circumstances, and the experience and judgment of our management, who continually evaluate the judgments, estimates and assumptions and may employ outside experts to assist in the evaluations.

Vasomedical, Inc. and Subsidiaries

Certain of our accounting policies are deemed “critical”, as they are both most important to the financial statement presentation and require management’s most difficult, subjective or complex judgments as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a discussion of our critical accounting policies, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K/A for the year ended May 31, 2010. The following accounting policies are effective for the current interim reporting period.

Effective June 1, 2010, the Company adopted Accounting Standards Update No. 2009-13, “Revenue Recognition (Topic 605)”, which revised the authoritative guidance for revenue arrangements with multiple deliverables. This revised authoritative guidance requires companies to allocate revenue in arrangements involving multiple deliverables based on the estimated selling price of each deliverable, even though such deliverables are not sold separately either by a company itself or other vendors. This revised authoritative guidance eliminates the requirement that all undelivered elements must have objective and reliable evidence of fair value before a company can recognize the portion of the overall arrangement fee that is attributable to items that already have been delivered. As a result, the new guidance may allow some companies to recognize revenue on transactions that involve multiple deliverables earlier than under previous requirements. This revised authoritative guidance was effective for revenue arrangements entered into or materially modified in fiscal years beginning on or after December 15, 2009. The adoption of this guidance did not have an impact on the Company’s consolidated condensed financial statements.

In July 2010, the Company adopted Accounting Standards Update (“ASU”) No. 2010-20, “Receivables (Topic 310): Disclosures about the Credit Quality of Financing Receivables and the Allowance for Credit Losses,” (ASU 2010-20). ASU 2010-20 requires enhanced disclosures about an entity’s credit quality of financing receivables and the related allowance for credit losses. The provisions of ASU 2010-20 will require expansion of the Company’s disclosures on the credit quality of its financing receivables and the allowance for credit losses. The adoption of this guidance did not have an impact on the Company’s consolidated condensed financial statements.

New Accounting Pronouncements

As of February 28, 2011, the Company believes that there are no recently issued accounting pronouncements not yet effective that will have an impact on the Company’s consolidated condensed financial statements.

Consolidated Results of Operations

Three Months Ended February 28, 2011 and February 28, 2010

Total revenue for the three months ended February 28, 2011 and February 28, 2010, was \$5,851,007 and \$1,107,398, respectively, which represented an increase of \$4,743,609, or 428—%. We reported net income applicable to common stockholders of \$217,657 for the third quarter of fiscal year 2011 compared to a net loss applicable to common stockholders of \$103,571 for the third quarter of fiscal 2010. The change from a net loss to net income was primarily attributable to operating income of \$669,164 in our Sales Representation segment partially offset by an operating loss of \$176,579 in our Equipment segment.

We defer recognition of commission revenue until the underlying equipment is accepted, which may take several months or longer. For the three months ended February 28, 2011, our deferred revenue additions were \$9.2 million, net of estimated future adjustments, and we recognized \$3.3 million from previously deferred revenue. Our deferred revenue additions were favorably impacted in our third fiscal quarter due to seasonal patterns in our Sales Representation segment. However, due to provisions in the GEHC Agreement, which took effect in January 2011,

that postpone our ability to bill certain amounts until later in the sales order cycle, deferred revenue additions are also expected to be generally lower in future quarters as compared to the third quarter of fiscal year 2011. These provisions have no impact on the timing of revenue recognition. In addition, as discussed in Note C, we are entitled to commissions on certain undelivered sales orders received by GEHC prior to our agreement and transferred to us from GEHC as of September 30, 2010. These transferred orders, though subject to various risks including potential cancellation and changes in credit worthiness and availability, as well as the Company's continued compliance under the GEHC Agreement, generated commission revenue of \$1.5 million from December 2010 to February 2011, and are expected to generate additional commission revenues estimated to range from \$2.1 million to \$3.0 million over approximately one or more years.

Vasomedical, Inc. and Subsidiaries

Revenues

Revenue in our Equipment segment increased 2% to \$1,129,232 for the three-month period ended February 28, 2011 from \$1,107,398 for the same period of the prior year. Equipment segment revenue from equipment sales decreased approximately 3% to \$571,213 for the three-month period ended February 28, 2011 as compared to \$589,283 for the same period in the prior year. The decrease in equipment sales is due primarily to a decrease in the average per unit sale price.

The decrease in the sales price per unit for the third quarter of fiscal 2011 reflects a shift in the product mix to more refurbished equipment sold. We anticipate that demand for EECP® systems will remain soft unless there is greater clinical acceptance for the use of EECP® therapy in treating patients with angina or angina equivalent symptoms who meet the current reimbursement guidelines, or a favorable change in current reimbursement policies by CMS or third party payors to consider EECP therapy as a first-line treatment option for angina or cover some or all Class II & III heart failure patients. Patients with angina or angina equivalent symptoms eligible for reimbursement under current policies include many with serious comorbidities, such as heart failure, diabetes, peripheral vascular disease and/or others.

Equipment segment revenue from equipment rental and services increased 8% to \$558,019 in the third quarter of fiscal 2011 from \$518,115 in the third quarter of fiscal year 2010. Revenue from equipment rental and services represented 49% of total Equipment segment revenue in the third quarter of fiscal 2011 and 47% in the same quarter of fiscal 2010. The increase in revenue generated from equipment rentals and services is due primarily to increased accessory parts shipments.

Commission revenues in the Sales Representation segment were \$4,721,775 in the third quarter of fiscal 2011. As discussed in Note B, the Company defers recognition of commission revenue until underlying equipment acceptance is complete. As of February 28, 2011, \$11,504,219 in deferred commission revenue was recorded in the Company's consolidated condensed balance sheet, of which \$984,737 is long-term.

Gross Profit

The Company recorded gross profit of \$4,113,435 in the third quarter of fiscal 2011 compared to \$633,724 in the third quarter of the prior fiscal year. Equipment segment gross profit decreased to \$476,175, or 42% of Equipment segment revenues, for the third quarter of fiscal 2011 compared to \$633,724, or 57% of Equipment segment revenues, for the same quarter of fiscal 2010. Gross profits are dependent on a number of factors, particularly the mix of new and refurbished EECP® systems and the mix of models sold, their respective average selling prices, the mix of EECP® units sold, rented or placed during the period, the ongoing costs of servicing EECP® systems, and certain fixed period costs, including facilities, payroll and insurance.

Sales Representation segment gross profit was \$3,637,270 for the three months ended February 28, 2011. Cost of commissions of \$1,084,505 reflects commission expense associated with recognized commission revenues. Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is earned.

Vasomedical, Inc. and Subsidiaries

Operating Income/(Loss)

Operating income was \$330,348 for the three months ended February 28, 2011 as compared to an operating loss of \$135,092 for the three months ended February 28, 2010. The change from an operating loss to operating income was primarily attributable to operating income of \$669,164 in our Sales Representation segment, partially offset by an operating loss of \$176,579 in our Equipment segment.

Selling, general and administrative (“SG&A”) expenses for the third quarter of fiscal 2011 and 2010 were \$3,671,288, or 63% of revenues, and \$667,123, or 60% of revenues, respectively, reflecting an increase of \$3,004,165 or approximately 450%. The increase in SG&A expenditures in the third quarter of fiscal 2011 resulted primarily from increased wages, benefits, commissions, and insurance expenses related to the Sales Representation segment.

During the third quarter of fiscal 2011, the Company recorded a provision for doubtful accounts and commission adjustments of \$667,362 as compared to the third quarter of fiscal year 2010 when there was no change to the Company’s provision for doubtful accounts and commission adjustments. Of the fiscal 2011 provision, \$12,651 was to accrue for bad debt expense and \$654,711 was to reduce gross deferred revenues for estimated adjustments.

Research and development (“R&D”) expenses of \$111,799, or 2% of revenues, for the third quarter of fiscal 2011 increased by \$10,106, or 10%, from \$101,693, or 9% of revenues, for the third quarter of fiscal 2010. The increase is primarily attributable to an increase in product development expenses.

Interest and Financing Costs

Interest and financing costs for the third quarter of 2011 was \$1,356 compared to the same period in the prior fiscal year when there were no interest and financing costs. Interest and financing costs consisted of interest on a short-term note to finance the Company’s insurance premiums.

Interest and Other Income, Net

Interest and other income for the third quarter of 2011 and 2010, were \$1,256 and \$(297), respectively. Interest income reflects interest earned on the Company’s cash balances and financing receivables.

Amortization of Deferred Gain on Sale-leaseback of Building

The amortization of deferred gain on sale-leaseback of building for the third quarter of fiscal years 2011 and 2010 was \$13,311. The gain resulted from the Company’s sale-leaseback of its facility.

Income Tax Benefit/(Expense), Net

During the third quarter of fiscal year 2011, we recorded income tax expense of \$3,026 and in the third quarter of fiscal year 2010, we recorded an income tax benefit of \$18,507. The fiscal 2010 income tax benefit was primarily a research and development credit associated with the federal stimulus package of 2009.

Nine Months Ended February 28, 2011 and February 28, 2010

Total revenue for the nine months ended February 28, 2011 and February 28, 2010, was \$10,927,596 and \$3,262,899, respectively, which represented an increase of \$7,664,697, or 235---%. We reported a net loss applicable to common stockholders of \$3,635,745 for the first three quarters of fiscal year 2011 compared to a net loss applicable to common

stockholders of \$301,615 for the first three quarters of fiscal 2010. The increase in net loss was primarily attributable to an operating loss of \$2,963,588 in our Sales Representation segment and by an operating loss of \$162,365 in our Equipment segment. Initial expenses associated with the start up of our Sales Representation segment were the main drivers of its operating loss.

Vasomedical, Inc. and Subsidiaries

These initial expenses are mainly personnel costs associated with hiring and maintaining our field sales force in advance of obtaining the GEHC Agreement and our early months of operation under the agreement. Conversely, we defer recognition of commission revenue until the underlying equipment is accepted, which may take several months or longer. As a result, our expenses substantially exceeded the revenue recognized for the same period while our deferred revenue continued to grow. In the nine months ended February 28, 2011, our deferred revenue additions of \$16.4 million, net of estimated future adjustments, exceeded amounts recognized of \$4.8 million from previously deferred revenue, reflecting this early stage pattern. Our deferred revenue additions were favorably impacted in our third fiscal quarter due to seasonal patterns in our Sales Representation Segment. However, due to provisions in the GEHC Agreement, which took effect in January 2011, that postpone our ability to bill certain amounts until later in the sales order cycle, deferred revenue additions are also expected to be generally lower in future quarters as compared to the third quarter of fiscal year 2011. These provisions have no impact on the timing of revenue recognition. In addition, as discussed in Note C, we are entitled to commissions on certain undelivered sales orders received by GEHC prior to our agreement and transferred to us from GEHC as of September 30, 2010. These transferred orders, though subject to various risks including potential cancellation and changes in credit worthiness and availability, as well as the Company's continued compliance under the GEHC Agreement, generated commission revenue of \$2.0 million from October 2010 to February 2011, and are expected to generate additional commission revenues estimated to range from \$2.1 million to \$3.0 million over approximately one or more years.

Revenues

Revenue in our Equipment segment increased 28% to \$4,187,197 for the nine-month period ended February 28, 2011 from \$3,262,899 for the same period of the prior year. Equipment segment revenue from equipment sales increased approximately 46% to \$2,484,488 for the nine-month period ended February 28, 2010 as compared to \$1,700,440 for the same period in the prior year. The increase in equipment sales is due primarily to higher volume.

Average per unit sales price was essentially unchanged, as a shift in product mix to more new systems offset decreases in average selling prices for both new and refurbished equipment. We anticipate that demand for EECP® systems will remain soft unless there is greater clinical acceptance for the use of EECP® therapy in treating patients with angina or angina equivalent symptoms who meet the current reimbursement guidelines, or a favorable change to current reimbursement policies by CMS or third party payors to consider EECP therapy as a first-line treatment option for angina or cover some or all Class II & III heart failure patients. Patients with angina or angina equivalent symptoms eligible for reimbursement under current policies include many with serious comorbidities, such as heart failure, diabetes, peripheral vascular disease and/or others.

Equipment segment revenue from equipment rental and services increased 9% to \$1,702,709 in the first three quarters of fiscal 2011 from \$1,562,459 in the first three quarters of fiscal year 2010. Revenue from equipment rental and services represented 41% of total Equipment segment revenue in the first three quarters of fiscal 2011 and 48% in the same quarters of fiscal 2010. The increase in revenue generated from equipment rentals and services is due primarily to more accessory parts shipped and an increase in the service business.

Commission revenues in the Sales Representation segment were \$6,740,399 in the first three quarters of fiscal 2011. As discussed in Note B, the Company defers recognition of commission revenue until underlying equipment acceptance is complete. As of February 28, 2011, \$11,504,219 in deferred commission revenue was recorded in the Company's consolidated condensed balance sheet, of which \$984,737 is long-term.

Vasomedical, Inc. and Subsidiaries

Gross Profit

The Company recorded gross profit of \$7,113,218 in the first three quarters of fiscal 2011 compared to \$1,810,224 in the first three quarters of the prior fiscal year. Equipment segment gross profit increased to \$1,881,237, or 45% of Equipment segment revenues, for the first three quarters of fiscal 2011 compared to \$1,810,224, or 55% of Equipment segment revenues, for the same quarters of fiscal 2010. Gross profits are dependent on a number of factors, particularly the mix of new and refurbished EEC[®] systems and the mix of models sold, their respective average selling prices, the mix of EEC[®] units sold, rented or placed during the period, the ongoing costs of servicing EEC[®] systems, and certain fixed period costs, including facilities, payroll and insurance.

Sales Representation segment gross profit was \$5,321,981 for the nine months ended February 28, 2011. Cost of commissions of \$1,508,418 reflects commission expense associated with recognized commission revenues. Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is earned.

Operating Loss

Operating loss was \$3,399,884 for the nine months ended February 28, 2011 as compared to \$462,017 for the nine months ended February 28, 2010. The increase in loss was due primarily to the initial expenses and deferral of revenue related to the Sales Representation segment, which resulted in a \$2,963,588 operating loss.

Selling, general and administrative (“SG&A”) expenses for the first three quarters of fiscal 2011 and 2010 were \$10,184,835, or 93% of revenues, and \$1,966,155, or 60% of revenues, respectively, reflecting an increase of \$8,218,680 or approximately 418%. The increase in SG&A expenditures in the first three quarters of fiscal 2011 resulted primarily from increased wages, benefits, commissions, professional fees, and insurance expenses related to the Sales Representation segment. The segment’s sales force and management staff has been receiving compensation since April 1, 2010, three months prior to the start of the GEHC Agreement.

During the first three quarters of fiscal 2011 the Company recorded a provision for doubtful accounts and commission adjustments of \$1,290,897 as compared to the first three quarters of fiscal year 2010, when the Company’s provision for doubtful accounts and commission adjustments was reduced by \$37,208. Of the fiscal 2011 provision, \$12,651 was to accrue for bad debt expense and \$1,278,246 was to reduce gross deferred revenues for estimated adjustments.

Research and development (“R&D”) expenses of \$328,267, or 3% of revenues, for the first three quarters of fiscal 2011 increased by \$22,181, or 7%, from \$306,086, or 9% of revenues, for the first three quarters of fiscal 2010. The increase is primarily attributable to an increase in product development and regulatory affairs expenses.

Interest and Financing Costs

Interest and financing costs for the first three quarters of 2011 was \$7,852 compared to the same period in the prior fiscal year when there were no interest and financing costs. Interest and financing costs primarily consisted of interest for the notes payable that were settled in June 2010, interest on short term notes due to related parties, and interest on a short-term note to finance the Company’s insurance premiums.

Interest and Other Income, Net

Interest and other income for the first three quarters of 2011 and 2010, were \$17,400 and \$86,155, respectively. In the first three quarters of fiscal year 2010 other income primarily consisted of a cash settlement of a lawsuit against one of

the Company's competitors. Interest income reflects interest earned on the Company's cash balances and financing receivables.

Vasomedical, Inc. and Subsidiaries

Amortization of Deferred Gain on Sale-leaseback of Building

The amortization of deferred gain on sale-leaseback of building for the first three quarters of fiscal years 2011 and 2010 was \$39,934. The gain resulted from the Company's sale-leaseback of its facility.

Income Tax Benefit\Expense, Net

During the first three quarters of fiscal year 2011 we recorded an expense for income taxes of \$10,356. During the first three quarters of fiscal year 2010 we recorded an income tax benefit of \$34,313. The 2010 income tax benefit was primarily a research and development credit associated with the federal stimulus package of 2009 and a reduction in the provision for estimated taxes.

Liquidity and Capital Resources

Cash and Cash Flow

We have financed our operations primarily from working capital, and the issuance of the Company's Series E Preferred Stock. At February 28, 2011, we had cash and cash equivalents of \$2,073,025, short-term investments of \$69,709 and working capital of \$3,081,699 compared to cash and cash equivalents of \$481,679, short-term investments of \$68,850 and working capital of \$1,263,691 at May 31, 2010.

Cash used in operating activities was \$2,059,901 during the first nine months of fiscal year 2011, which consisted of a net loss after adjustments to reconcile net loss to net cash of \$1,602,388, and cash used by operating assets and liabilities of \$457,513. The changes in the account balances primarily reflect increases in accounts payable of \$161,439, accrued commissions of \$2,665,691, accrued expenses and other liabilities of \$629,008, sales tax payable of \$19,512, deferred revenue of \$11,581,820, trade payable due to related party of \$1,910, and other long-term liabilities of \$249,214, and a decrease in inventory of \$368,215. These changes were offset by a decrease in accrued professional fees of \$9,908, a decrease in accrued rent expense of \$2,768, and an increase in deferred commission expense of \$2,283,967, other current assets of \$64,823, other assets of \$217,759, finance receivables of \$49,925 and accounts and other receivables of \$13,505,172. Net trade receivables for our Equipment Segment were 18% of revenues for the nine-month period ended February 28, 2011, as compared to 24% of revenues for the nine-month period ended February 28, 2010. Trade receivables turnover for our Equipment Segment was 5.27 times for the nine months ended February 28, 2011 as compared to 3.41 times for the nine months ended February 28, 2010. As discussed in Note B, the Company defers recognition of commission revenue until underlying equipment acceptance is complete.

Investing activities during the nine-month period ended February 28, 2011 used cash of \$133,129 for purchases of property and equipment and reinvestment of interest earned on a certificate of deposit.

Financing activities during the nine-month period ended February 28, 2011 provided cash of \$3,784,376 consisting of net proceeds from issuance of preferred stock. Notes payable of \$250,000 were issued and subsequently repaid during the nine months ended February 28, 2011.

Liquidity

During the last several years, the Company has incurred operating losses. We have sought to achieve profitability by expanding our business opportunities through the introduction of additional products and the development of the Vaso

Healthcare business.

In the last couple of years, the Company has been looking to diversify its business, including offering additional medical devices in its product portfolio, and has since introduced patient monitoring devices (the BIOX series Holter, ABP recorders and analysis software) and patient management devices (the EZ ECG and EZ O2 products) into the U.S. market.

Page 23

Vasomedical, Inc. and Subsidiaries

In the first three quarters of fiscal 2011, the Company issued Series E convertible preferred stock (see Note M) to finance the operation of its Sales Representation segment. In addition, under the terms of our agreement with GEHC, we are entitled to commissions on certain undelivered sales orders received by GEHC prior to our agreement and transferred to us from GEHC as of September 30, 2010. These transferred orders, though subject to various risks including potential cancellation and changes in credit worthiness and availability, as well as the Company's continued compliance under the GEHC Agreement, generated commission revenue of \$2.0 million from October 2010 to February 2011, and are expected to generate additional commission revenues estimated to range from \$2.1 million to \$3.0 million over approximately one or more years.

Based on our current operations through February 28, 2011, we believe internally generated funds from our Equipment and Sales Representation segments will be sufficient for the Company to continue operations through at least February 28, 2012. At March 31, 2011, the Company had cash and cash equivalents in excess of \$9.75 million.

Vasomedical, Inc. and Subsidiaries

ITEM 4 - CONTROLS AND PROCEDURES

In our Annual Report for the year ended May 31, 2010, as filed with the SEC on Form 10-K on August 30, 2010, we reported a material weakness in internal controls, as defined by the Public Company Accounting Oversight Board. The material weakness arose from a lack of adequate accounting resources to address non-routine transactions and certain financial reporting matters on a timely basis, which was in the process of being remedied, as reported by the Company.

The Company believes the changes made to enhance its accounting resources and financial reporting processes, including the hiring of a new Chief Financial Officer and the appointment of a financial expert as the Chairman of the Audit Committee, were sufficient to remedy the previously existing material weakness.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of February 28, 2011, our disclosure controls and procedures are effective to provide reasonable assurances that such disclosure controls and procedures satisfy their objectives and that the information required to be disclosed by us in the reports we file under the Exchange Act is recorded, processed, summarized and reported within the required time periods.

Vasomedical, Inc. and Subsidiaries

PART II - OTHER INFORMATION

ITEM 6 – EXHIBITS:

Exhibits

31 Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to Rules 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32 Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Vasomedical, Inc. and Subsidiaries

In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VASOMEDICAL, INC.

By: /s/ Jun Ma
Jun Ma

President & Chief Executive Officer
(Principal Executive Officer)

/s/ Jonathan Newton .
Jonathan Newton

Chief Financial Officer

Date: April 14, 2011

